Locoregional versus systemic therapy - robust positive data remain elusive
Nat Rev Clin Oncol
.
2018 Sep;15(9):537-538.
doi: 10.1038/s41571-018-0047-6.
Authors
Marco Sanduzzi-Zamparelli
1
2
3
,
Jordi Bruix
4
5
6
Affiliations
1
Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain.
2
CIBER of Hepatic and Digestive Diseases (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
3
August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain.
4
Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain.
[email protected]
.
5
CIBER of Hepatic and Digestive Diseases (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
[email protected]
.
6
August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain.
[email protected]
.
PMID:
29858583
DOI:
10.1038/s41571-018-0047-6
No abstract available
Publication types
Comment
MeSH terms
Carcinoma, Hepatocellular*
Chemoembolization, Therapeutic*
Humans
Liver Neoplasms*
Neoplasm Recurrence, Local
Sorafenib
Substances
Sorafenib
Grants and funding
16-0026/AICR_/Worldwide Cancer Research/United Kingdom